NBIX News and Press, Neurocrine Biosciences Inc. From 05/03/24

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 PR Newswire CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolesce...

2024-05-02 10:00:11 ET Sumant Kulkarni from Canaccord Genuity issued a price target of $164.00 for NBIX on 2024-05-02 08:45:00. The adjusted price target was set to $164.00. At the time of the announcement, NBIX was trading at $143.03. The overall price target consensus ...

2024-05-01 12:47:00 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional...

2024-05-01 12:38:10 ET Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Conference Call May 1, 2024 08:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - C...

2024-05-01 07:12:26 ET More on Neurocrine Biosciences Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcrip...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules PR Newswire SAN DIEGO , April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has a...

2024-04-30 11:50:12 ET More on Neurocrine Biosciences Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcrip...

2024-04-29 15:08:53 ET Summary AbbVie Inc.'s shares dropped last week due to concerns about the erosion of Humira and despite the company beating revenue and EPS expectations. Humira's global sales fell 36% YoY, but AbbVie's other growth products performed well, leading to overall...

2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...